Treatment of bone disorders

专利摘要:

公开号:DK200600250U1
申请号:DK200600250U
申请日:2006-09-26
公开日:2007-01-12
发明作者:Atherton Nigel Derek；Joseph W Totten；Gaitonde Michael David
申请人:Shire Holdings Ag；
IPC主号:

专利说明:

DK 2006 00250 U4
Use of a lanthanum carbonate for the manufacture of a medicament
BRIEF DESCRIPTION OF THE MOVEMENT
This invention relates to the use of a lanthanum carbonate for the manufacture of a medicament for the treatment or prevention of osteoporosis.
BACKGROUND OF THE MAKING
Throughout life, old bone is continuously removed by bone-absorbing osteoclasts and replaced with new bone formed by osteoblasts. This cycle is called the bone remodeling cycle and is usually highly regulated, ie. The function of osteoclasts and osteoblasts is connected so that the same amount of bone as is resorbed is formed in a stable state.
The bone remodeling cycle takes place in specific areas of the bone surfaces. Osteoclasts formed by suitable bone precursor cells resorb parts of bone; new bone is then generated by osteoblast activity. Osteoblasts synthesize the collagen precursors in the bone matrix and also regulate its mineralization. The dynamic activity of osteoblasts in the bone remodeling cycle to meet skeletal growth and matrix requirements and also to regulate its maintenance and mechanical function is thought to be influenced by various factors such as hormones, growth factors, physical activity and other stimuli. Osteoblasts are thought to have receptors for parathyroid hormone and estrogen. Osteoclasts are adhered to the surface of bone undergoing resorption and are thought to be activated by some form of osteoblast signal.
Irregularities in one or more stages of the bone remodeling cycle (for example, where the balance between bone formation and resorption is lost) can lead to bone remodeling disorders or metabolic bone disorders.
2 2GB 2006 00250 U4
Osteoporosis, Paget's disease and English sufferers are examples of such diseases. Some of these diseases are caused by overactivity in one half of the bone remodeling cycle as compared to the other, i.e. of osteoclasts or osteoblasts. For example, in osteoporosis, there is a relative increase in osteoclast activity that can cause bone density and mass reduction. Osteoporosis is the most common of the metabolic bone disorders and can either be a primary disease or be secondary to another or other diseases.
Postmenopausal osteoporosis is currently the most common form of osteoporosis. Old-age osteoporosis affects older patients of both genders, and younger individuals suffer from osteoporosis in some cases.
Cheese porosity is generally characterized by loss of bone density. Thinning and weakening of the bones leads to higher fracture incidence due to minimal trauma. The most common bone fracture in postmenopausal osteoporosis occurs on the wrist and spine. Old man osteoporosis is characterized by a higher fracture incidence of femur than average.
While osteoporosis as a therapeutic target has been and continues to attract a great deal of interest, the close link between osteoblast and osteoclast activities in the bone remodeling cycle makes it an extremely difficult challenge to replace already lost bone. Therefore, research into treatments for the prevention and prophylaxis of osteoporosis (as opposed to replacement of already lost bone) has yielded greater results to date.
Estrogen deficiency has been thought to be a major cause of postmenopausal osteoporosis. Steroids, including estrogen, have actually been used as therapeutic agents {New Eng. J. Med., 303, 1195 (1980)). However, recent studies have concluded that other causes must be found (J. din. Invest., 77, 1487 (1986)).
3 DK 2006 00250 U4
Other bone disorders can be caused by an irregularity in the bone remodeling cycle, resulting in both increased bone resorption and increased bone formation. The covenant disease is one such example.
Lanthan has previously had a prominent role in medical science due to its ability to form stable phosphate complexes. This use has manifested itself in the treatment of hyperphosphataemia using lanthanum carbonate. US Patent No. 5, 968,976 discloses the preparation and use of certain hydrates of lanthanum carbonate in a pharmaceutical composition for the treatment of hyperphosphataemia.
Fernandez-Gavarron et al. (Bone and Mineral, 283-291 (1988)) report studies on the incorporation of 140-lanthanum in bone, teeth and hydroxyapatite in vitro. While the uptake depth ranged from an estimated 5 to 15 pm (depending on experimental conditions), it was the authors' conclusion that replacing calcium with lanthanum in hydroxyapatite may provide increased resistance to acid-induced solution. On the basis of this suggested increased resistance to acid, the authors indicate that Lanthan's clinical utility as an aid in treating diseases such as osteoporosis, root caries and alveolar bone resorption may need to be investigated.
Vijai S. Shankar et al. (Biochemical and Biophysical Research Communications, 907-912 (1992)) report that extracellular use of lanthanum (III) induced a concentration-dependent increase of cytosolic calcium in osteoclasts. The authors indicated that the osteoclast calcium receptor may be sensitive to activation and inactivation by the trivalent cation lanthanum.
4 4GB 2006 00250 U4
Bernd Zimmermann et al. (European Journal of Cell Biology, 114-121 (1994)) report that lanthanum inhibited endochondral mineralization and reduced calcium accumulation in organoid cultures of mesodermal "limb bud" cells.
SUMMARY OF PRODUCTION
Surprisingly, it has been found that lanthanum (III) compounds promote bone formation and bone density and have beneficial effects on bone cell activity and differentiation.
Therefore, the present invention relates to the use of a lanthanum carbonate for the manufacture of a medicament for treating or preventing osteoporosis by oral administration to a mammal.
In one embodiment of the invention, the effective amount of lanthanum carbonate is from 0.01 mg / kg / day to 100 mg / kg / day, preferably from 0.05 mg / kg / day to 50 mg / kg / day or at from 0.1 mg / kg / day to 10 mg / kg / day.
The drug may further contain at least one bone enhancing agent. Examples of suitable bone promoting agents include a synthetic hormone, a natural hormone, estrogen, calcitonin, tamoxifen, a biophosphonate, a biphosphonate analog, vitamin D, a vitamin D analogue, a mineral supplement, a statin drug, a selective estrogen receptor modulator, and sodium fluoride.
These and other aspects of the invention will become apparent upon reference to the following detailed description and appended drawings. In addition, reference is made herein to various publications.
5 DK 2006 00250 U4
BRIEF DESCRIPTION OF THE DRAWINGS
The invention will be better understood by reference to the following drawings, in which:
FIG. Figure 1 is a bar graph showing the combined results of the LA's effect on bone resorption, where the bars represent the relative CrossLaps mean amounts per osteoclast ± SD at different lanthanum concentrations;
FIG. 2 is a bar graph showing the combined results of LA's effect on osteoblast differentiation, with the bars representing the relative TRAP 5b activities ± SD at different lanthanum concentrations;
FIG. 3 is a bar graph showing the combined results of the effect of LA on osteoblast differentiation, with the columns representing the relative specific activities of + SD for cellular alkaline phosphatase at different lanthanum concentrations; and
FIG. Figure 4 is a bar graph showing the combined results of the effect of LA on the bone formation activity of mature osteoblasts, the bars representing the amount of calcium released (mmol / L) from the bone nodules after HCl extraction. ± SD at different lanthanum concentrations.
DETAILED DESCRIPTION OF THE MOVEMENT
As mentioned above, the present invention provides the use of a lanthanum carbonate for the manufacture of a medicament for treating or preventing osteoporosis by oral administration to a mammal. Bone formation, or osteogenesis, refers to the creation of new bone mass. This includes the process of forming new bone structure or increasing existing bone density. Osteoblasts form bone by producing extracellular organic matrix, or osteoid, and then mineralize the matrix to form bone. The major mineral component of bone is crystalline hydroxyapetite, which comprises a large proportion of the mass in normal adult bone. Surprisingly, we have found that lanthanum significantly promotes bone formation in vitro and in vivo. Increased bone formation in vitro was observed when lanthanum (III) was added to cultures of mature osteoblasts in vitro at concentrations of 100 to 15000 ng / ml. Increased bone formation was quantified by measuring the amount of calcium incorporated into bone nodules formed by the osteoblasts.
Lanthan carbonate can be used to treat or prevent osteoporosis in a variety of mammals, including farmed animals such as pigs, cattle, horses, sheep and goats, and also extensive pets and experimental mammals such as dogs, cats and rodents.
In one embodiment of the invention, the mammal is a human with osteoporosis.
Osteoporosis can be hereditary or acquired and is generally systemic and affects the entire skeletal system.
Osteoporosis is a common bone remodeling disorder characterized by a decrease in bone density in normally mineralized bone, resulting in dilution and increased porosity of the bone cortex and trabeculae. The skeletal fragility caused by osteoporosis predisposes those affected to bone pain and increased incidence of fractures. Progressive bone loss in this condition can result in a loss of up to 50% of the initial skeletal mass.
Primary osteoporosis includes idiopathic osteoporosis that occurs in children or young adults with normal gonadal function, Type I osteoporosis, also described as post-menopausal osteoporosis, and Type II osteoporosis, yarn 7 7 ældreDK 2006 00250 than 70 years. Causes of secondary osteoporosis may be endocrine (eg glucocorticoid excess, hyperparathyroidism, hypoganodism), drug induced (eg corticosteroid, heparin, tobacco) and miscellaneous (eg chronic renal failure, liver disease and malabsorption syndrome osteoporosis). As used herein, the phrase "at risk of developing a bone impairment" is envisaged to include mammals and humans with a higher-than-average predisposition for developing a bone impairment. For example, those at risk for osteoporosis include postmenopausal women , older men (for example, those over 65 years of age) and those in treatment with drugs known to cause osteoporosis as a side effect (e.g., steroid-induced osteoporosis). Certain factors are well known in the art for use in Identify those at risk of developing bone dysfunction due to bone remodeling disorders such as osteoporosis Important factors include low bone mass, family history, lifestyle, estrogen or androgen insufficiency and negative calcium balance Postmenopausal women are at particular risk of developing osteoporosis. the following are referenced references for the treatment of bone disease to include treatment and / or prophylaxis, except where indicated otherwise in the context.
A variety of lanthanum carbonates can be used according to the invention, preferably lanthanum carbonate in a form which is bioavailable. Preferred lanthanum carbonates are lanthanum carbonate hydrate and lanthanum carbonate.
An effective amount of lanthanum for use in the present invention is an amount of lanthanum carbonate that will provide the desired beneficial or therapeutic effect after administration according to the prescribed regimen. Non-limiting examples of an effective amount of lanthanum carbonate can range from approx. 0.01 mg / kg / day to approx. 100 mg / kg / day, preferably from about 8DK 2006 00250 U4 0.05 mg / kg / day to approx. 50 mg / kg / day, and especially from ca. 0.1 mg / kg / day to approx. 10 mg / kg / day.
The dose may also be selected so as to provide an effective plasma concentration of lanthanum.
Examples of an effective lanthanum concentration plasma concentration may range from approx. 0.1 ng / ml to approx. 1 000 ng / ml, preferably from ca. 1 ng / ml to approx. 500 ng / ml, especially from ca. 1 ng / ml to approx. 100 ng / ml.
Furthermore, the dose may be selected so as to provide an effective amount of lanthanum in and around the bone surface.
Examples of effective amounts in and around the largest bone surfaces may range from 0.1 pg / g to 500 pg / g, preferably from 0.5 pg / g to 100 pg / g, especially from 1 pg / g to 25 pg. / g.
The lanthanum carbonate may be administered in the form of a pharmaceutical composition comprising the active ingredient in admixture or association with a pharmaceutically acceptable carrier or diluent. The active ingredient should be formulated in a composition suitable for oral administration. Orally administered compositions may, if desired, contain one or more physiologically compatible carriers and / or excipients and may be solid or liquid. The compositions may be of any convenient form including, for example, tablets, coated tablets, capsules, lozenges, aqueous or oily suspensions, solutions, emulsions, syrups, elixirs and dry products suitable for reconstitution with water or other suitable liquid vehicle. Before use. The compositions can advantageously be prepared in unit dosage form. Tablets and capsules may, if desired, contain conventional ingredients such as binders, for example, syrup, acacia, gelatin, sorbitol, tragacanth or polyvinylpyrrolidone; fillers, for example 9 LK 2006 00250 U4 lactose, sugar, corn starch, calcium phosphate, sorbitol or glycine; lubricants, for example magnesium stearate, talcum, polyethylene glycol or silica; explosives, for example potato starch; or acceptable wetting agents, such as sodium lauryl sulfate. Tablets may be coated according to methods well known in the art.
Liquid compositions may contain conventional additives such as suspending agents, for example, sorbitol syrup, mehyl cellulose, glucose / sugar syrup, gelatin, hydroxymethyl cellulose, carboxymethyl cellulose, aluminum stearate gel or hydrogenated edible fats; emulsifiers, for example lecithin, sorbitan monooleate or acacia; non-aqueous vehicles which may include edible oils, for example, vegetable oils such as arachis oil, almond oil, fractionated coconut oil, fish oil, oily esters such as polysorbate 80, propylene glycol, or ethyl alcohol; and preservatives, for example, methyl or propyl p-hydroxybenzoates or sorbic acid. Liquid compositions can conveniently be encapsulated in, for example, gelatin to obtain a unit dosage form.
Formulations for oral administration may be formulated in a sustained release formulation such that lanthanum is delivered into the colon. This will decrease the interaction between lanthanum and dietary phosphate, resulting in precipitation of lanthanum phosphate which is poorly absorbed in the gut. Delayed-release formulations are well known in the art and include, for example, delayed-release or hourly capsules, osmotic delivery capsules, etc.
It may be advantageous to incorporate an antioxidant, for example ascorbic acid, butylated hydroxy anisole! or hydroquinion, in the compositions to increase their durability.
t 10 10DK 2006 00250 U4
Administration may consist of one or more cycles; during these cycles, one or more periods of osteoclast and osteoblast activity will occur and one or more periods of no osteoclast or osteoblast activity.
Alternatively, administration may be performed in an uninterrupted regimen; such a regime can be a long-term regime, for example a permanent regime.
It is to be understood that the dosage of the compositions and the duration of administration will vary depending on the needs of the particular individual. The exact dose regimen will be determined by the attending physician or veterinarian, who will take into account such factors as body weight, age and symptoms (if any). The compositions may, if desired, incorporate one or more additional active ingredients.
During the dosing regimen, administration may be performed once or several times a day, for example once, twice, three or four times a day.
If desired, the lanthanum carbonate can be administered simultaneously or sequentially with other active ingredients. These active ingredients may include, for example, other drugs or compositions which are capable of interacting with the bone remodeling cycle and / or which may be used in fracture repair. Such drugs or compositions may be, for example, those useful in the treatment of osteoporosis.
Bone promoters known in the art to increase bone formation, bone density or bone mineralization or prevent bone resorption can be used in the drug. Suitable bone enhancers include natural or synthetic hormones such as estrogens, androgens, calcitonin, prostaglandins and parathormone; growth factors, such as platelet-derived growth factors, insulin-like growth factor, transforming growth factor, epidermal growth factor, connective tissue growth factors, and fibroblast growth factor; vitamins, especially vitamin D; minerals such as calcium, aluminum strontium and fluoride; statin drugs, including pravastatin, fluvastatin, sim-vastatin, lovastatin, and atorvastatin; agonists or antagonists of surface receptors of osteoblasts and osteroclasts, including parathormone receptors, estrogen receptors, and prostaglandin receptors; biphosphonates and bone anabolic agents:
Figures 1 to 4 show the effect of lanthanum (III) ion on bone resorption, osteoclast differentiation, osteoblast differentiation and bone formation, respectively.
Subsequent examples describing the effect of a lanthanum (III) ion-containing solution in in vitro bone culture assays and in an in vivo study illustrate the present invention.
Example 1 In vitro bone resorption assay
Test substance
The test substance was lanthanum carbonate tetrahydrate (hereinafter lanthanum carbonate). 1 mg of lanthanum is equivalent to 1.9077 mg of lanthanum carbonate. Lanthan carbonate was dissolved in 2M HCl to give a concentration of 28.6 mg / ml (i.e., 15 mg / ml lanthanum). Aliquots of this starting solution were diluted with 2M HCl to obtain solutions of varying concentrations so that adding one microliter of these solutions in the culture medium gave the final test concentrations of 100, 500.1000, 5000 and 15000 ng / ml lanthanum in culture medium. These solutions / concentrations are referred to hereinafter as LA100, LA500, LA1000, LA5000 and LA15000.
12 DK 2006 00250 U4
control Substances
We used control groups in each assay to show that the assays were able to detect the effect of inhibition (bone resorption assay and osteoclast differentiation assay) or activation (osteoblast differentiation and bone formation). The control substances used were:
Bafilomycin A1 (in bone resorption assay) 17-β estradiol (in osteoblast differentiation assay and bone formation assay).
In the osteoclast differentiation assay, the control group did not contain vitamin D.
The method of osteoclast culture on bone slices was originally described by Boyde et al. (1984) and by Chambers et al (1984). As a cell culture, we used a method that was slightly modified from the original methods (Lakkakorpi et al. 1989, Lakkakorpi and Våånån, 1991). The rate of bone resorption in the cultures was initially determined by counting the number of resorption pits on each bone or dentine disk using a phase contrast microscope (Sundquist et al. 1990). Later, the pits were visualized using Wheat Germ Agglutinin Lectin that specifically binds to the resorbed region of bone (Selander et al.
1994), which makes it possible to quantify the total resorbed area using a microscope and computer-aided image analysis system (Laitala and Våånånan 1994, Hentunen et al. 1995) We used a commercially available method (CrossLaps for cultures, Osteometer Biotech, Herlev, Denmark) to detect the amount of collagen cross-links released in the culture medium as an index of bone resorption rate (Bagger et al., 1999).
30 The study protocol uses a method in which osteoclasts are grown on bone slices and allowed to resorb bone. The system is ideal for determining the effect of drug candidates on bone resorbing activity of osteoclasts. Drug candidates are added to the cell cultures at the beginning of the culture period and the osteoclasts are allowed to resorb bone for 3 days. The amount of bone resorbed during the culture period is determined and compared to the amount of bone resorbed in control cultures (those grown in the absence of drug candidates). If the drug candidate inhibits the function of osteoclasts, the amount of bone resorbed in these cultures is significantly lower than in the control cultures.
Procedure:
Transverse 0.1 mm thick cortex bone slices were excised from the diaphysis of fresh bovine femora (Atria Slaughterhouse, Oulu, Finland) using a low-speed diamond saw, cleaned with ultrasonification in multiple replacements of sterile distilled water and stored at 4 ° C before use. . Long bones were sampled from 1-day-old rat pups killed by decapitation. The bones were exposed free of adherent soft parts, and enosous surfaces were curated with a scalpel knife into the osteoclast culture medium (Dulbecco's Modified Eagle's Medium (DMIEM), (Gibco BRL, Paisley, UK) supplemented with 100 IU / ml penicillin, 100 pg / ml streptomycin). Penicil-lin / streptomycin solution, Gibco, BRL, Paisley, UK), 20 mM HEPES buffer (Gibco BRL, Paisley, UK), and 10% heat-inactivated fetal serum, pH 6.9 (Gibco BRL, Paisley, UK). dispersed cells and bone fragments were stirred using a plastic pipette. Larger fragments were allowed to settle for a few seconds and the supernatant was seeded on the bone slices pre-wetted in the medium. After a 30 minute precipitation period at 37 ° C, the bone slices were washed at immersion in fresh medium and then transferred to wells in 24-well culture dishes containing osteoclast culture medium. The bone slices were incubated in a moistened atmosphere with 95% air and 5% carbon dioxide at 37 ° C for 72 hours.
t 14 14DK 2006 00250 U4
After the culture period, the amount of bone resorption was determined by measuring the amount of collagen crosslinking delivered in the culture medium using a commercial kit (CrossLaps for Cultures, Osteometer Biotech) according to the manufacturer's instructions. The number of osteoclasts in each culture was determined by microscope counting the amount of TRAP-positive multi-nuclear cells, and the results are given as the number of collagen cross-links released per one osteoclast.
In this study, the effect of lanthanum (III) ion on the bone resorption activity of osteoclasts was tested.
The following sample groups were included:
Baseline (including vehicle)
Control (Baseline + 10 nM bafilomyxin A1)
Baseline + 100 ng / ml lanthanum Baseline + 500 ng / ml lanthanum Baseline + 1000 ng / ml lanthanum Baseline + 5000 ng / ml lanthanum Baseline + 15000 ng / ml lanthanum
Six replicas were included in each group and the test was performed twice. Ba-filomycin A1, a very potent inhibitor of osteoclast V-ATPase proton pump, was used as a control to demonstrate the ability of the test system to detect bone resorption inhibition.
Tables of Results: In the bone resorption assay, the CrossLaps (nm) mean amount delivered into the culture medium was determined and the number of osteoclasts in the corresponding cultures was calculated. CrossLaps averages were divided by the number of osteoclasts in the corresponding cultures, and the results are given in Table 1 as relative CrossLapps averages per osteoclasts. The relative values were obtained by dividing each individual value by the baseline gap average.
5
Table 1: Relative CrossLaps averages per osteoclast in the first bone resorption assay.
Group 1 2 3 4 5 6 Mean ± SD Baseline 0.98 0.82 1.01 1.65 0.74 0.81 1.00 + 0.34 Control 0.00 0.00 0.00 0.19 0 , 27 0.14 0.10 ± 0.11 (***) LA 100 0.57 0.56 1.13 0.78 0.71 0.71 0.74 ± 0.21 LA 500 1.04 0 , 58 1.38 0.75 0.88 0.63 0.88 ± 0.30 LA 1000 1.14 1.09 0.89 1.76 1.07 1.11 1.18 ± 0.30 LA 5000 1.39 0.78 2.70 1.18 0.76 1.21 1.34 ± 0.71 LA 15000 0.57 0.58 0.57 0.96 2.53 1.11 1.05 ± 0 , 76 10 Table 2: Relative CrossLaps Mean Per Osteoclasts in the Second Bone Resorption Assay
Group 1 2 3 4 5 6 Mean ± SD Baseline 0.75 1.33 0.88 1.98 0.53 0.53 1.00 ± 0.56 Control 0.00 0.00 0.00 0.00 0.00 .00 0.00 0.00 ± 0.00 (***) LA 100 0.38 0.75 0.78 0.94 0.67 0.96 0.74 ± 0.21 LA 500 0.50 2 14 0.50 1.03 0.47 0.63 0.88 ± 0.65 LA 1000 0.70 0.59 1.69 1.40 1.68 0.73 1.13 ± 0.51 LA 5000 0.48 1.18 0.77 0.98 1.99 1.81 1.20 ± 0.59 LA 15000 0.29 1.08 0.62 0.87 0.47 0.45 0.63 ± 0 , 29
All the data shown in Tables 1 and 2 were combined and analyzed. The combined results are shown in Table 3 and Figure 1.
16 DK 2006 00250 U4
Table 3: Combined results of the effect of LA 100 - LA 15000 on bone resorption
Group Number Mean ± SD Baseline 12 1.00 ± 0.44 Control 12 0.00 + 0.00r *) LA 100 12 0.74 ± 0.20 LA 500 12 0.88 ± 0.48 LA 1000 12 1, 15 ± 0.40 LA 5000 12 1.27 ± 0.63 LA 15000 12 0.84 ± 0.59 5
Results In the bone resorption assay, there was no significant effect of the lanthanum (III) ion on either the amount of CrossLaps delivered into the culture medium or on the number of osteoclasts. The control substance, bafilomycin A1, completely inhibited bone resorption. As shown in Table 3 and Figure 4, the lanthanum (III) ion has no statistically significant effects on the bone resorption activity of individual mature osteoclasts at any of the concentrations tested. However, the dose-dependent inhibition of bone resorption with the lower concentrations 15 (LA 100 and LA 500) should be noted. The slight decrease seen with LA 15000 may be due to weak toxic effects of this high concentration.
References: 20 Bagger YZ, Foged NT, Andersen L, Lou H, Quist P (1999) CrossLaps for culture: An improved enzyme-linked immunosorbent assay (ELISA) for measurable bone resorption in vitro. J Bone Miner Res 14, Suppl. 1, S370.
17 17DK 2006 00250 U4
Boyde A, Ali NN, Jones SJ (1984) Resorption of dentine by isolated osteo-clasts in vitro. Br. Dcnt J 156: 216-220.
Chambers TJ, Revell PA, Fuller K, Athanasou NA (1984) Resorption of bone by isolated rabbit osteociasts. J Cel I Sci 66: 383-399.
Hentunen TA, Lakkakorpi PT, Tuukkanen J, Lehenkari PP, Sampath TK, Våånånen BK (1995) Effects of recombinant human osteogenic protein-1 on the differentiation of osteoclast-like cells and bone resorption. Biochem Biophys Res Commun 209: 433-443.
Laitala T, Våånånen HK (1994) Inhibition of bone resorption in vitro by anti-sense RNA and DNA molecules targeted against carbonic anhydrase II or two subunits of vacuolar H + -ATPase. J Clin Invest 93: 2311-2318.
Lakkakorpi F, Tuukkanan I, Hentunen T, Jårvelin K, Våånån HK (1989) Organization of osteoclast microfilaments during attachment to bone sur-face in vitro. In Bone Miner Res 4: 8 17-825.
Lakkakorpi PT, Våånånen HK (1991) Kinetics of the osteoclast cytoskeleton during the in vitro resorption cycle. J Bone Miner Res 6: 817,826.
Selander K, Lehenkari P, Våånånen HK (1994) The effects of bisphosphon ates on the resorption cycle of isolated osteociasts. Calcif Tissue Int 55: 368-375.
Sundquist K, Lakkakorpi P, Wallmark B, Våånånen HK (1990) Inhibition of osteoclast proton transpot by bafilomycin Ai abolishes bone resorption. Biochem Biophys Res Commun 168: 309-313.
18 DK 2006 00250 U4
Example 2 In vitro osteoclast differentiation assay
A method known as mouse bone marrow culture system is one of the most widely used for investigating osteoclast differentiation. Originally, this method was developed by Takahashi et al. (1988a). Mouse bone marrow osteoclast precursors can be induced to form multinucleated osteoclast-like cells (MNCs) in the presence of either an active metabolite of vitamin D3 (1.25 (OH) 2D3) or parathyroid hormone (PTH). MNCs formed in mouse bone marrow cultures have been shown to possess several features characteristic of osteoclasts. They form pits on bone or dentine discs (Takahashi et al. 1988a, Hattersleyog Chambers 1989, Shinaretal. 1990); they express high levels of tartrate-resistant acid phosphatase (TRAP) and calcitonin receptors (Takahashi et al. 1988b, Shinaret al. 1990); and they respond to calcitonin (Takahashi et al. 1988a) and prostaglandin E2 (Collins and Chambers 1992) The method is thus an ideal method to investigate both stimulators and inhibitors of osteoclast differentiation.
In the original culture system, osteoclast formation was determined after culture for 8 days. In bone marrow, both non-adherent osteoclast precursors and stromal cells are present, the latter of which are required to support osteoclast formation. The number of osteoclasts formed is generally determined by counting the number of TRAP-positive MNCs containing at least three nuclei (Takahashi et al. 1988a). In the negative control, where 1.25 (OH) 2D3 is not added, TRAP-positive MNCs are not formed.
We modified the original assay to culture 1 x 10 6 mouse marrow cells / ml for 6 days. With this modification, the number of TRAP-positive MNCs / cultures has been shown to be approx. 150 (Choi et al. 1998, Hentunen et al. 1998). Instead of counting the number of differentiated osteoclasts formed, we measured the amount of TRAP released from osteoclasts into the culture medium using a fast single TRAP immunoassay (Halleen et al.
19 19DK 2006 00250 U4 1999) presentation at the Annual Meeting of the American Society for Bone and Mineral Research, September 30 - October 4,1999, ί St. Louis, MO, USA. Our results show that the amount of TRAP released into the culture medium correlates significantly (r = 0.94, p <0.0001, n = 120) with the amount of osteoclasts formed.
Procedure: 8-10 week old mice were killed with CO2. Tibia and femora were released from adherent soft parts. The cone ends were cut with a scalpel and the marrow was rinsed with α-Minimal Essential Medium (α-MEM, Gibco BRL, Paisley, UK), supplemented with 100 IU / ml penicillin and 100 pg / ml streptomycin. A 10 ml needle with a 27 gauge needle was used for rinsing. Cells were centrifuged at 600 x G for 10 minutes and the cell pellet resuspended in α-MEM containing 10% fetal calf serum. Cells were allowed to adhere to plastic for 2 hours at 37 ° C in a 5% CO2 incubator to obtain monocyte and macrophage removal. Non-adherent cells were duly removed and the adherent bone marrow cells were cultured in 24-well plates (1 x 10 6 cells / well = 1 ml) for 6 days. Half of the medium was replaced by day 3 and the treatments were replaced. At the end of culture, the plates were fixed with 2% paraformaldehyde in PBS for 20 minutes. Osteoclast formation was determined by measuring TRAP activity from the culture medium using the novel TRAP immunoassay (vide infra) using a polyclonal TRAP antiserum generated in rabbits against purified human bone TRAP. The TRAP antibody was bound to anti-rabbit IgG coated microtiter wells (Gibco BRL, Paisley, UK), and TRAP media was then bound to the antibody. The activity of bound TRAP was measured in sodium acetate buffer using pNPP as substrate.
In this study, the effect of the lanthanum (III) ion on osteoclast differentiation was tested in the presence of 1,25-dihydroxyvitamin D3. The following sample groups were included:
Baseline (including vehicle)
Control (Baseline without 1,25-dihydroxyvitamin D3)
Baseline + 100 ng / ml lanthanum Baseline + 500 ng / ml lanthanum Baseline + 1000 ng / ml lanthanum Baseline + 5000 ng / ml lanthanum Baseline + 15000 ng / ml lanthanum
Six replicas were included in each group and the test was performed twice. Baseline without 1,25-dihydroxyvitamin D3 was used as a control to show that the test system enables detection of inhibition of osteoclast differentiation. Since the results of LA 100 did not yield statistically the same result (significantly different or not compared to baseline) in both of the two tests, we performed the LA100 test once more.
Tables of Results: In the osteoclast differentiation assay, the amount of TRAP 5b activity released into the culture medium was determined as an index of osteoclast number. The results are shown as relative TRAP Sb activities obtained by dividing each individual TRAP 5b activity by the baseline group's TRAP 5b mean activity, 21 DK 2006 00250 U4
Table 4: Relative TRAP 5b activities in the first osteoclast differentiation assay
Group 1 2 3 4 5 6 Mean ± SD Baseline 1.32 0.72 0.43 0.45 1.89 1.18 1.00 + 0.57 Control 0.16 0.17 0.18 0.11 0 , 11 0.20 0.16 ± 0.14 (**) LA 100 0.81 0.96 0.43 1.39 0.98 0.65 0.87 ± 0.33 LA 500 0.73 0, 55 0.48 0.87 0.58 1.05 0.71 ± 0.22 LA 1000 0.58 0.82 0.35 0.40 0.98 0.45 0.60 ± 0.25 LA 5000 0 , 44 0.40 0.41 0.36 0.51 0.52 0.44 ± 0.06 (*) LA 15000 0.14 0.26 0.21 0.34 0.31 0.88 0.36 ± 0.27 (*) 5 Table 5: Relative TRAP 5b activities in the second osteoclast differentiation assay
Group 1 2 3 4 5 6 Mean ± SD Baseline 1.27 1.37 0.98 0.92 0.74 0.71 1.00 ± 0.27 Control 0.17 0.34 0.14 0.10 0 , 11 0.06 0.15 ± 0.10 (***) LA 100 0.64 0.66 0.62 0.36 0.33 0.62 0.54 ± 0.15 (**) LA 500 1.16 1.30 0.85 1.33 0.76 1.01 1.07 ± 0.24 LA 1000 0.70 0.78 0.34 0.65 0.69 1.00 0.69 ± 0 , 21 LA 5000 0.94 0.46 0.21 0.72 0.68 0.33 0.56 ± 0.27 (*) LA 15000 0.22 0.31 0.35 0.25 0.15 0 0.25 ± 0.07 (***)
The LA 100 assay was repeated once again because the results were significantly different from baseline in the second assay and not significantly different in the first assay.
22 DK 2006 00250 U4
Table 6: Relative TRAP 5b activities in the third LA 100 osteoclast differentiation assay.
Group 1 2 3 4 5 6 Mean ± SD Baseline 1.25 1.20 0.76 0.93 1.07 0.81 1.00 ± 0.20 Control 0.08 0.07 0.20 0.10 0 , 0.13 0.14 ± 0.07 (***) LA 100 0.71 0.96 0.42 0.47 0.87 0.69 0.69 ± 0.21 (*) 5 All the The data shown in Tables 4-6 were combined and analyzed. The combined results are shown in Table 7 and Figure 2.
Table 7: Combined results of the effect of LA 100 - LA1 5000 on osteoclast differentiation
Group Number Mean ± SD Baseline 18 1.00 ± 0.36 Control 18 0.15 ± 0.07 (***> LA 100 18 0.70 ± 0.27 (**) LA 500 12 0.89 ± 0 , 29 LA 1000 12 0.65 + 0.23 (**) LA 5000 12 0.50 ± 0.20 {***) LA 15000 12 0.30 ± 0.19 (***) Results: In the osteoclast differentiation assay a clear dose-dependent inhibition was observed with LA 500 - LA 15000, which was statistically significant from LA 1000 to LA 15000. A statistically significant inhibition was also observed with the LA 100.1 control group, where vitamin D was omitted, osteoclast differentiation was significantly lower than in baseline group.
23 DK 2006 00250 U4
references
Halleen N, Alatalo S, Hentunen TA, Våånånen HK (1999) A novel TRAP 5b immunoassay for osteoclast cultures. J. Bone Miner Res 14, Suppl. 1, S244.
Choi SJ, Deviin RD. Menaa C, Chung H, Roodman GD, Reddy SV (1998) Cloning and identification of human Sca as a novel inhibitor of osteoclast formation and bone resorption. J Clin Invest 102: 1360-1368.
Collins DA, Chambers TJ (1992) Prostaglandin E2 promotes osteoclast formation in murine hematopoietic cultures through an action of hematopotetic cells. J Bone Miner Res 7: 555-561.
Hattersley G, Chambers TJ (1989) Generation of osteoclastic function in mouse bone marrow cultures: multinuclearity and tartrate-resistant acid phosphatase are unreliable markers for osteoclastic differentiation. Endocrinology 124: 1689-1696.
Hentunen TA, Reddy SV. Boyce BF, Dovlin R, Park HR, Chimg H, Selander KS, Dallas M, Kurihara N, Galson OL, Goldring SR, Koop, BA Windle JJ, Roodman GD (1998) Immortalization of osteoclast precursors by targeting bcl-Xi_ and simian virus 40 large T antigen to the osteoclast lineage in trans-genic mice. J. Clin Invest 102: 88-97.
Shinar DM, Sato M, Rodan GA (1990) The effect of hemopoietic growth factors on the generation of osteoclast-like cells in mouse bone marrow cultures. Endocrinology 126: 1728-1735.
Takahashi N, Yamana H, Yoshiki S, Roodman GD, Mundy GR, Jones SJ, Boyde A, Suda T (1988a) Osteoclast-like cell formation and its regulation by 24 24DK 2006 00250 U4 osteotropic hormones in mouse bone marrow cultures. Endocrinology 122: 1373-1382.
Takahashi N. Akatsu T, Sasaki T, Nicholson GC, Moseley JM, Martin TJ, Suda T (1988b) Induction of calcitonin receptors by 1,25-dihydroxyvitam / n D3 in osteoclast-like multinucleated cells formed from mouse bone marrow cells. Endocrinology 123: 1504-1510.
Example 3 In vitro osteoblast differentiation assay
Osteoblasts are bone-forming cells that arise from mesenchymal stem cells. During the development of osteoblasts, three distinct periods have been identified and defined: 1) cell proliferation and extracellular matrix secretion (ECM); 2) ECM maturation; and 3) ECM mineralization. During these periods, sequential expression of osteoblast phenotype markers has been characterized. Alkaline phosphatase is associated with the bone cell phenotype and is actively expressed during the maturation of the osteoblast. When mineralization occurs, large amounts of calcium are deposited in the mature organic matrix to form bone-like nodes. By following these markers, we are able to investigate all the steps of osteoblast differentiation in this culture system.
Several methods have been developed for the study of osteoblasts. The first of these invades isolation of cells from calvaria with the osteoblast phenotype. However, these cells represent only the mature stages of osteoblasts, since only a small portion of the calvaria cells are osteoblast precursors (Bellows and Au-bin 1989; Bellows et al. 1994). Osteoblast cell lines are convenient to use, but they may not behave as primary osteoblasts (Mundy 1995). It is conceivable that osteoblast precursors are present in bone marrow (Friedenstein 1976; Owen 1988), and bone marrow stromal cells have long been recognized as the source of osteoprogenitor cells.
25 25DK 2006 00250 U4
We have established a culture model in which mouse bone marrow-derived osteo-progenitor cells first proliferate and then differentiate into osteoblasts capable of forming mineralized bone nodules (Qu et al. 1998; Qu et al. 1999). We confirmed this by following the expression of several markers of the osteoblast phenotype and by examining the morphology of the culture at the light and electron microscope level. Synthesis of fibrillar extracellular matrix with late deposition of calcium confirmed differentiation and maturation of osteoblasts. Thus, this culture system meets the requirements of an in vitro model applicable to the study of osteoprogenitor cell differentiation for bone synthesizing osteoblasts.
Procedure:
Bone marrow cells were obtained from femora from 10-week-old NMRI female mice. Animals were killed by cervical dislocation. Both femora were removed and soft parts were released aseptically. Metaphyses from both ends were cut and bone marrow cells were collected by rinsing the diaphysis with culture medium: phenol red-free-α modified essential medium (α-MEM (Gibco BRL, Paisley, UK)). A bone marrow cell suspenson was obtained by repeated aspiration of the cell preparation through a 22 gauge needle and nucleated cells were counted with a hemocytometer. Cells were plated with 106 cells / cm 2 in T-75 tissue culture flasks in phenol red-free α-MEM supplemented with 10% FCS, 10'8 M dexamethasone, 50 pg / ml ascorbic acid, 10'2 M sodium β-glycerophosphate, 100 IU / ml penicillin and 100 µg / ml streptomycin. The cells were cultured for 6 days and half of the medium was replaced after 3 days. On day 6, subcultures were prepared. Cells were washed with warm PBS and adherent cells were released using trypsin-EDTA. Trypsized cells were passed through a 22 gauge needle syringe to produce a single-cell suspension, counted and plated in 24-well plates at a density of 5 x 10 3 cells / ml. These osteoprogenitor cells were stimulated to differentiate against mature osteoblasts by culturing them in the presence of 26 26DK 2006 00250 U4 10'10 M estrogen (17 β-estradiol) for 8 days. The test substances were added at the beginning of the secondary culture without estrogen and each time the medium was replaced.
The number of osteoblasts formed was determined by measuring cellular alkaline phosphatase (ALP) activity in the culture. Cells were disrupted by washing the cell layers twice with PBS, extracting to 200 μ! 0.1% Triton X-100 buffer at pH 7.6 (Sigma, St. Louis, MO, USA) and freezing overnight. ALP activity was determined colorimetrically using p-nitrophenyl phosphate as substrate at pH 9.7 and determination of the optical density at 405 nm. In parallel, the protein content of the wells was determined with the BIO-RAD protein assay, and the specific ALP activity is expressed as units / mg of protein.
In this study, the effect of the lanthanum (III) ion on osteoblast differentiation was tested. The following sample groups were included:
Baseline (+ vehicle)
Control (Baseline + 10'10 M 17 β-estradiol)
Baseline + 100 ng / ml lanthanum Baseline + 500 ng / ml lanthanum Baseline + 1000 ng / ml lanthanum Baseline + 5000 ng / ml lanthanum Baseline + 15000 ng / ml lanthanum
Results tables:
Osteoblast differentiation was determined by measuring cellular alkaline phosphatase (ALP) activities and total protein amounts from cell lysates. The ALP activities were divided by the corresponding amounts of protein to obtain specific activities of ALP. The results are shown as relative specific activities obtained by dividing each individual value by the baseline group mean.
Table 8: Relative Specific Activities of Intracellular Alkaline Phosphatase in the Preliminary Osteoblast Differentiation Assay
Group 1 2 3 4 Mean ± SD Baseline 0.94 1.10 0.94 1.02 1.00 + 0.07 Control 1.10 1.32 1.31 1.29 1.26 ± 0.10 (* *) LA 100 0.98 1.29 1.19 1.12 1.15 ± 0.13 LA 500 0.96 0.98 0.99 1.11 1.01 ± 0.07 LA 1000 0.69 1 , 13 0.92 1.01 0.94 ± 0.19 LA 5000 0.42 0.46 0.50 0.48 0.47 + 0.03 (***) LA 15000 0.51 0.49 0 , 47 0.54 0.5Q ± 0.03 (***)
Table 9: Relative specific activities of intracellular alkaline phosphatase in the first osteoblast differentiation assay
Group 1 2 3 4 5 6 7 8 Mean ± SD Baseline 0.97 0.94 1.12 0.98 0.97 1.06 0.99 0.96 1.00 ± 0.06 Control 1.01 1.20 1 , 04 1.13 1.19 1.06 1.03 1.14 1.10 ± 0.08 (**) LA 100 1.25 0.98 1.31 0.77 0.95 1.04 1, 13 0.98 1.05 ± 0.17 LA 500 0.83 1.03 1.02 0.98 0.95 0.96 0.82 0.62 0.90 ± 0.14 LA 1000 1.01 1 , 12 1.06 0.76 1.01 0.78 0.93 0.81 0.94 ± 0.14 LA 5000 0.54 0.48 0.47 0.63 0.54 0.59 0.44 0.55 0.53 ± 0.06 (***) LA 15000 0.40 0.42 0.53 0.36 0.39 0.35 0.30 0.43 0.40 ± 0.07 (* **) 28 DK 2006 00250 U4
Table 10: Relative specific activities of intracellular alkaline phosphatase in the second osteoblast differentiation assay
Group 1 2 3 4 5 6 Mean ± SD Baseline 0.99 0.83 1.25 1.01 0.88 1.04 1.00 ± 0.15 Control 1.00 1.18 1.53 1.52 1 , 03 1.38 1.27 ± 0.24 (*) LA 100 0.91 0.94 1.34 1.20 1.00 1.43 0.14 ± 0.22 LA 500 0.88 0.89 1.10 1.09 0.75 0.90 0.93 + 0.14 LA 1000 0.73 0.71 1.19 0.81 0.72 1.09 0.88 ± 0.21 LA 5000 0, 31 0.51 0.51 0.49 0.28 0.40 0.41 ± 0.10 (***) LA 15000 0.27 0.13 0.33 0.32 0.29 1.31 0, 28 ± 0.07 (***) 5 All the data shown in Tables 8-10 were combined and analyzed. The combined results are shown in Table 11 and Figure 3.
Table 11: Combined results of the effect of LA 100 - LA15000 on osteoblast differentiation 10
Group Number Mean + SD Baseline 18 1.00 ± 0.09 Control 18 1.19 ± 0.17 (***) LA 100 18 1.10 ± 0.18 (*) LA 500 18 0.94 ± 0, 13 LA 1000 18 0.92 + 1.17 LA 5000 18 0.48 ± 0.09 (***) LA 15000 18 0.38 ± 0.11 (***) Results:
The lanthan (III) ion exhibited a distinct dose-dependent response in the osteoblast differentiation assay. The highest test concentrations (LA 5000 and LA
29 29GB 2006 00250 U4 15000) inhibited and the lowest test concentration (LA 100) significantly activated osteoblast differentiation. No significant response was observed with LA 500 and LA 1000. The control substance, 17-β estradiol, significantly activated osteoblast differentiation.
references:
Bellows CG, Aubin JE (1989) Determination of the number of osteo-progenitors in isolated fetal rat calvarial cells in vitro. Devfop Biol 113: 8-13.
Bellows CG, Wang YH, Heersche JN, Aubin JE (1994) 1,25-dihydroxyvitamin D3 stimulates adipocytic differentiation in cultures of fetal rat calvarial cells: comparison with the effects of dexamethasone. Endocrinology 134: 2221.2229.
Friedenstein AJ (1976) Precursor cells of mechanocytes. Int Rev Cytol 47: 327-355.
Mundy RG (1995) Osteoblasts, bone formation and mineralization. In: Bone remodeling and its disorders. Martin Dunitz Ltd. pp. 29-30.
Owen M. Friedenstein AJ (1988) Stromal stem cells: Marrow-derived osteo-genic precursors. Ciba Found Symp 136: 42-60.
Qu Q, Perålå-Heape M, Kapanen A, Dahllund J, Salo J, Våånån, HK, Hårkonen. P (1998) Estrogen enhances differentiation of osteoblasts in mouse bone marrow culture. Bone 22: 201.209.
Qu Q, Hårkonen PL, Våånån HK (1999) Comparative effects of estrogen and antiestrogens on differentiation of osteoblasts in mouse bone marrow culture, J Cell Biochem 73: 500-507, 30 30DK 2006 00250 U4
Example 4 In Vitro Bone Formation Assay
The activity of mature osteoblasts can be determined by quantifying their ability to form mineralized bone matrix. This is done by demineralizing the bone matrix formed and determining the amount of calcium released. Thus, this culture system meets the requirements of an in vitro model useful for the study of the bone formation activity of mature osteoblasts.
Procedure:
The mature osteoblasts obtained during the 8-day secondary culture in the absence of estrogen and any test substances described above were allowed to form bone nodules by growing them for an additional 7 days. At the end of the growing period, the amount of calcium deposited during the growing period was determined and the amount of bone formation (calcium deposition) was regained.
To quantify the amount of deposited calcium, the cell cultures were washed three times with Ca 2+ and Mg 2+ -free PBS and incubated overnight at room temperature in 0.6 M HCl. Extracts of 50 μΙ were pooled with 1 ml of determined o-cresol-phthalein complex. The colorimetric reaction was determined at 570 nm in a spectrophotometer. Absolute calcium concentrations were determined by comparison with a calibrated standard provided by the vendor.
In this study, the effect of lanthanum carbonate on bone formation was tested. The following sample groups were included: 31 DK 2006 00250 U4
Baseline (including vehicle)
Control (Baseline + 10'10M 17 β-estradiol)
Baseline + 100 ng / ml lanthanum Baseline + 500 ng / ml lanthanum 5 Baseline + 1000 ng / ml lanthanum
Baseline + 5000 ng / ml lanthanum Baseline + 15000 ng / ml lanthanum
Tables of Results: 10 The amount of bone formation was determined by measuring the amount of calcium deposited in bone nodules formed by mature osteoblasts. The results are shown as the amount of calcium released (mmol / L) from the bone nodules after HCl extraction. The baseline values are too low to show the results using relative amounts, as was done in the other assays.
Table 12: Calcium deposition (mmol / L in the preliminary bone formation assay
Group 1 2 3 4 Mean ± SD Baseline 0 0 0 0 0.00 ± 0.00 Control 0.04 0 0 0.04 0.02 ± 0.02 LA 100 0 0 0 0 0.00 ± 0.00 LA 500 0 0 0 0.09 0.02 ± 0.05 LA 1000 0.10 0 0.11 0.05 0.07 ± 0.05 (*) LA 5000 0.59 1.64 0.39 1.62 1.0610.660 LA 15000 1.48 0.16 0.50 1.41 0.89 ± Q, 66 (***) 32 DK 2006 00250 U4
Table 13: Calcium deposition (mmol / L) in the first bone formation assay
Group 1 2 3 4 5 6 Mean ± SD Baseline 0 0 0 0.02 0.02 0 0.01 ± 0.01 Control 0.15 0.21 0.14 0.10 0.15 0.16 0.15 ± 0.04 (***) LA 100 0.04 0.17 0.01 0.27 0 0.14 0.11 ± 0.11 (*) LA 500 0.44 0.15 1.32 0, 27 1.31 1.10 0.77 ± 0.54 (***) LA 1000 0.95 1.66 1.47 1.41 1.00 1.25 1.29 ± 0.28 (***) ) LA 5000 1.31 1.55 1.56 1.52 1.40 1.39 1.46 ± 0.10 (***) LA 15000 1.46 1.42 1.56 1.11 1.11 1.08 1.29 ± 0.21 (***) Table 14: Calcium deposition (mmol / L) in the second bone formation assay Group 1 2 3 4 5 6 7 8 Mean ± SD Baseline 0 0.01 0 0.01 0 0 0.02 0 1.01 ± 0.01 Control 0.22 0.14 0.16 0 0.16 0 0.10 0.16 0.12 ± 0.08 (**) LA 100 0.04 0 , 18 0 0 0 0.28 0.14 0 0.08 ± 0.11 LA 500 1.17 0.30 1.41 0 0.02 0.46 1.17 1.40 0.62 ± 0.61 (*) LA 1000 1.09 0.81 1.34 1.56 1.76 0.02 1.52 1.02 1.14 ± 0.55 (***) LA 5000 1.70 1.44 1 64 1.52 1.08 1.63 1.30 1.48 1.47 + 0.20 (***) LA 15000 1.24 1.46 1.22 1.68 1.62 1.18 1 , 1.56 1.40 ± 0.21 (***)
The data shown in Tables 13 and 14 were combined and analyzed. The results from Table 12 were not included as there was no significant difference between baseline and control groups. The combined results are shown in Tables 15 and 10 Figure 4.
33 DK 2006 00250 U4
Table 15: Combined results of the effects of LA 100 - LA 15000 on the bone formation activity of mature osteoblasts
Group Number Mean ± SD Baseline 14 0.01 ± 0.01 Control 14 0.13 ± 0.06 (***) LA 100 14 0.09 ± 0.10 (**) LA 500 14 0.68 ± 0 , 56 (***) LA 1000 14 1.20 ± 0.45 (***) LA 5000 14 1.47 ± 0.16 (***) LA 15000 14 1.35 ± 0.21 (** *) Results:
All concentrations of the tested lanthanum (III) ion showed highly significant activation of the bone formation activity of mature osteoblasts, the activation being highest with the highest test concentrations. The control substance, 17 β-estradiol, 10 activated bone formation significantly.
references
Bellows CG, Aubin JE (1989) Determination of the number of osteo-15 progenitors in isolated fetal rat calvarial cells in vitro. Dev Biol 113: 8-13.
Bellows CG, Wang YH, Heersche JN, Aubin JE (1994) 1,25-dihyroxyvitamin D3 stimulates adipocytic differentiation in cultures of fetal rat calvarial cells: comparison with the effects of dexamethasone. Endocrinology 134: 2221 -20 2229.
Friedenstein AJ (1976) Precursor cells of mechanocytes. Int Rev Cytol 47: 327-355.
34 DK 2006 00250 U4
Mundy RG (1995) Osteoblasts, bone formation and mineralization. In: Bone remodeling and its disorders. Martin Dunitz Ltd. pp. 29-30.
Owen M, Friedentein AJ (1988) Stromal stem cells: Marrow-derived osteo-genic precursors. Ciba Found Symp 136: 42-60.
Qu Q, Perålå-Heape M, Kapanen A, Dahllund J. Salo J, Våånån KH, Harkonen, P (1998) Estrogen enhances differentiation of osteoblasts in mouse bone marrow culture. Bone 22: 201-209.
Qa Q, Harkonen PL, Våånånen HK (1999) Comparative effects of estrogen and antiestrogens on differentiation of osteoblasts in mouse bone marrow culture. J. Cell Biochem 73: 500-507.
Previously in vitro studies
Species / race / age / gender Mice / NMRI <8-12 w, he and she
Rats, Sprague-Dawley, 1 day
Supplier
University of Turku, The Center of Experimental Animals, Turku, Finland University of Turku, The Center of Experimental Animals, Turku, Finland
Statistical analyzes of in vitro results
Mean and standard deviation (SD) in each group were determined. One-way analysis of variance (ANOVA) was used to examine whether the values obtained between different groups (baseline vs. controls and test substances) were statistically different (with p <0.05). Statistical significance is shown in each table and figure with asterisks, one asterisk (*) indicates a p value between 0.05 and 0.01, two asterisks (**) a p value between 0.01 and 0.001, and three DK-asterisks (***) a p -value of K 0.001. No asterisk indicates that the group results do not differ significantly from the corresponding baseline group results.
5 Summary of in vitro results
The effects of the lanthanum (III) ion test concentrations on bone cell activity and differentiation are summarized in Table 17, where (+) means significant activation, (-) significant inhibition, and (0) no effect. One character (+ or-) 10 means a p-value of between 0.05 and 0.01, two characters (++ or -) a p-value of between 0.01 and 0.001, and three characters (++ + or ---) a p-value <0.001.
Table 17: The effects of LA on bone cells 15
Dose Bone Osteoclast- Osteoblast- Bone ng / ml resorption differentiation differentiation formation 100 0 - + ++ 500 0 0 0 +++ 1000 0 - 0 +++ 5000 0 ... ... +++ 15000 0.. ... ... +++
CONCLUSIONS ON IN VITRO TESTS
The Lanthan (III) ion is a potent stimulator of the bone formation activity of mature osteoblasts at all concentrations tested, with the best responses observed at the highest test concentrations (LA 5000 and LA 15000). However, these concentrations may also have cytotoxic effects on the osteoblast precursor cells, which may compensate for the activation of mature osteoblasts in vivo.
LA 500 and LA 1000 also stimulate bone formation, but these concentrations do not impair the formulation of osteoblasts in the osteoblast differentiation assay, suggesting that they have no cytotoxic effects on osteoblast precursor cells. However, LA 1000 decreases osteoclast formation in the osteoclast differentiation assay, suggesting that it may have cytotoxic effects on osteoclast precursor cells. The only significant effect of LA 500 in the four assays was the activation of bone formation. Thus, this LA concentration may be useful for increasing bone formation without cytotoxic effects.
The LA 100 appears to activate both bone formation and osteoblast differentiation and inhibit osteoclast differentiation and bone resorption (although the inhibition of bone resorption is not statistically significant). All of these effects would strengthen bones.
Example 5 In vivo Bone Formation Study Procedure:
The samples taken from the hip bone of growing immature dogs were analyzed. The group was divided into a control and a treatment group. The treatment group received 1000 mg / kg / day lanthanum carbonate administered orally twice daily. The groups were run for 13 weeks, after which samples of bone were taken vertically through the hip bone, inserted into methyl methacrylate-based resin, divided into sections and stained with toluidine blue and Von Kossa fave. The parameters measured were: 37 37GB 2006 00250 U4. Tracheal and cortex bone mass. Osteoid surface and volume, Osteoblast surface. Cortex osteoid volume 5. Tracheal and cortex osteoclast numbers. Resorptive surfaces of cortex and trabecular bone, Incorporation of lanthanum into bones (modified soiochrome azure technique).
Results: 10
The hip bones of these animals act as a growth plate. Appearance as in immature actively growing animals. There was very active bone remodeling throughout the samples taken, and in addition, there appeared to be bone remodeling with very active periostal osteoclasm on the cortex surface and in the cortex 15 on the other.
There was a marked difference in cortex thickness between the different animals and pronounced variation in the amount of bone in the biopsy specimen. This degree of variation was not limited to either of the two groups of animals, or to animals of particular sex.
20
There was a statistically significant difference in trabecular bone volume between the two groups. Stomach bone volume was lower in the control group (about half that of the treatment group) than in the lanthanum-treated group. There was no statistically significant difference in any of the 25 other bone parameters examined between the two groups.
There was an increase in trabecular bone volume in treated animals (approximately twice) compared to the control group. These results suggest that lanthanum affects bone growth at the growth plate.
30

权利要求:
Claims (9)
[1]
Use of a lanthanum carbonate for the manufacture of a medicament for treating or preventing osteoporosis by oral administration to a mammal.
[2]
Use according to claim 1, characterized in that the mammal is a human.
[3]
Use according to claim 1 or 2, characterized in that osteoporosis is any of primary osteoporosis, secondary osteoporosis, post-menopausal osteoporosis, male osteoporosis and steroid-induced osteoporosis.
[4]
Use according to claims 1 to 3, characterized in that the lanthanum carbonate is a hydrate.
[5]
Use according to claim 4, characterized in that the lanthanum carbonate is selected from the group consisting of lanthanum carbonate hydrate and lanthanum carbonate tetra hydrate.
[6]
Use according to claims 1 to 5, characterized in that the effective amount of lanthanum carbonate is from 0.05 mg / kg / day to 50 mg / kg / day.
[7]
Use according to claim 6, characterized in that the effective amount of lanthanum carbonate is from 0.1 mg / kg / day to 10 mg / kg / day.
[8]
Use according to claims 1 to 7, characterized in that the medicament further comprises at least one bone promoting agent.
[9]
Use according to claim 8, characterized in that the bone promoting agent is selected from the group consisting of a synthetic hormone, a natural hormone, estrogen, calcitonin, tamoxifen, a biphosphonate, a biphosphonate analogue, Vitamin D, a D vitamin analog, a mineral supplement, a statin drug, a selective estrogen receptor modulator, and sodium fluoride.

类似技术:

---

公开号 | 公开日 | 专利标题

---

DK200600250U4|2008-09-12|Use of a lanthanum carbonate for the manufacture of a medicament

---

Howe et al.1992|The warfarin embryopathy: a rat model showing maxillonasal hypoplasia and other skeletal disturbances

---

JP2001506635A|2001-05-22|Compositions and methods for stimulating bone growth

---

Duarte et al.2009|The effects of caffeine administration on the early stage of bone healing and bone density: a histometric study in rats

---

Hung et al.2013|Antiosteoclastogenic activity of silicate-based materials antagonizing receptor activator for nuclear factor kappaB ligand–induced osteoclast differentiation of murine marcophages

---

Sakai et al.1999|Intermittent administration of human parathyroid hormone | prevents immobilization‐related bone loss by regulating bone marrow capacity for bone cells in ddY mice

---

US20180153940A1|2018-06-07|Compositions for treatment of osteochondral disorders

---

Castelo-Branco et al.2015|Use of ossein–hydroxyapatite complex in the prevention of bone loss: a review

---

Corrado et al.2005|Neridronate and human osteoblasts in normal, osteoporotic and osteoarthritic subjects

---

US20120213826A1|2012-08-23|Use of Pro-Inflammatory Compounds for Promoting Bone Formation

---

Chavassieux et al.1991|Effects of ossein-hydroxyapatite compound on ewe bone remodeling: biochemical and histomorphometric study

---

AU2007100227A4|2007-04-19|Use of lanthanum compounds for the treatment of bone diseases

---

US20100015246A1|2010-01-21|Combination of a lanthanum compound and bone enhancing agent for the treatment of bone diseases

---

Ferreira Junior et al.2018|Biometric, histomorphometric, and biochemical profile in atorvastatin calcium treatment of female rats with dexamethasone-induced osteoporosis

---

Rico et al.1993|β2-Microglobulin in postmenopausal osteoporosis

---

CA2278539A1|1998-07-30|Bone regeneration in osteoporosis using human bone marrow mesenchymal cells

---

Alshahrani2020|The effect of histamine-2 receptor antagonist on bone healing and implant osseointegration

---

Zariņš2020|Changes in Bone Structure Following Implantation of Biphasic and Triphasic Strontium Enriched Biomaterials in Animals with Experimental Osteoporosis. Summary of the Doctoral Thesis

---

Jagger et al.1994|O11. Bone formation induced by mechanical stimulation in rat caudal vertebrae is not dependent on bone resorption

---

DE20122679U1|2007-03-01|Use of lanthanum | compounds for enhancing bone formation, inhibiting osteoclastic differentiation and/or activating osteoblastic differentiation to treat bone disease such as osteoporosis

---

JPWO2017175625A1|2019-02-21|Composition for regulating bone metabolism

---

Cooper2005|Bone and Tooth Society Annual Meeting 2005

---

Quach2016|Comparing Local and Systemic Delivery of Bisphosphonate in Enhancing Bone Graft Success and A Pilot Study on Evaluating Bisphosphonate's Effect on Tooth Eruption

---

Behrends2017|Preclinical assessment of the influence of inflammation on bone regeneration

---

da Silva2017|Drug-induced bone regeneration in a diabetic model

同族专利:

---

公开号 | 公开日

---

US7078059B2|2006-07-18|

---

GB0015745D0|2000-08-16|

---

FI7569U1|2007-07-17|

---

EP2052725A2|2009-04-29|

---

EP1294384A2|2003-03-26|

---

EP1294384B1|2009-03-11|

---

CA2415228C|2011-09-06|

---

AU2001274341B2|2006-10-19|

---

DK200600250U4|2008-09-12|

---

DE60137929D1|2009-04-23|

---

AT424837T|2009-03-15|

---

WO2002000227A8|2004-04-15|

---

US20070048390A1|2007-03-01|

---

FIU20060389U0|2006-09-22|

---

AU7434101A|2002-01-08|

---

WO2002000227A2|2002-01-03|

---

AT9687U1|2008-02-15|

---

JP2004501198A|2004-01-15|

---

CA2415228A1|2002-01-03|

---

US20020051822A1|2002-05-02|

---

WO2002000227A3|2002-08-29|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

FR2493704B1|1980-11-07|1985-05-24|Lemouel Jean|

---

US5869473A|1988-08-02|1999-02-09|Bone Care International, Inc.|Method for treating and preventing hyperparathyroidism|

---

US5171583A|1988-10-21|1992-12-15|The Regents Of The University Of California|Treatment of osteoporosis using potassium bicarbonate|

---

US5342604A|1988-10-31|1994-08-30|The Dow Chemical Company|Complexes possessing ortho ligating functionality|

---

US5696239A|1988-10-31|1997-12-09|The Dow Chemical Company|Conjugates possessing ortho ligating functionality and complexes thereof|

---

GB9506126D0|1995-03-25|1995-05-10|Johnson Matthey Plc|Pharmaceutical composition and method|

---

US5902825A|1997-01-07|1999-05-11|Mitreoak, Ltd.|Composition and method for the palliation of pain associated with diseases of the bone and bone joints|

---

DE60120458T2|2000-10-13|2007-01-11|Abbott Laboratories, Abbott Park|METHOD FOR DETERMINING THE INITIAL DOSE OF VITAMIN D COMPOUNDS|

---

WO2004030669A1|2002-09-30|2004-04-15|Schering Corporation|Use of tricyclic amides for the treatment of disorders of calcium homeostasis|

---

SG145765A1|2003-08-26|2008-09-29|Shire Holdings Ag|Pharmaceutical formulation comprising lanthanum compounds|US20100015246A1|2000-06-27|2010-01-21|Shire International Licensing B.V.|Combination of a lanthanum compound and bone enhancing agent for the treatment of bone diseases|

---

US7858602B2|2000-10-16|2010-12-28|Rodriguez Victorio C|Therapeutic and prophylactic uses of cell specific carbonic anhydrase enzymes in treating aging disorders due to oxidative stress and as growth factors of stem cells|

---

WO2003094933A2|2002-05-08|2003-11-20|Shire Holding Ag|Use of lanthanum for the treatment of hypercalcemia and bone metastasis|

---

US20060083791A1|2002-05-24|2006-04-20|Moerck Rudi E|Rare earth metal compounds methods of making, and methods of using the same|

---

EP1647524A3|2002-08-14|2006-09-13|Altair Nanomaterials Inc.|Rare earth metal compounds, methods of making, and methods of using the same|

---

US20040161474A1|2002-05-24|2004-08-19|Moerck Rudi E.|Rare earth metal compounds methods of making, and methods of using the same|

---

WO2004037274A1|2002-10-22|2004-05-06|Genzyme Corporation|Amine polymers for promoting bone formation|

---

ES2394782T3|2003-05-07|2013-02-05|Osteologix A/S|Composition with strontium and vitamin D for the prophylaxis and / or treatment of cartilage and / or bone conditions|

---

WO2004098619A2|2003-05-07|2004-11-18|Osteologix A/S|Treating cartilage / bone conditions with water-soluble strontium salts|

---

PL1622629T3|2003-05-07|2013-12-31|Osteologix As|Controlled-release composition containing a strontium salt|

---

SG145765A1|2003-08-26|2008-09-29|Shire Holdings Ag|Pharmaceutical formulation comprising lanthanum compounds|

---

US7381428B2|2003-08-26|2008-06-03|Shire International Licensing B.V.|Stabilized lanthanum carbonate compositions|

---

JP4869229B2|2004-07-27|2012-02-08|シアファーマシューティカルズ，インク．|Pharmaceutical composition for treating hyperphosphatemia using lanthanum hydroxycarbonate|

---

JP2008516971A|2004-10-15|2008-05-22|アルテアーナノ，インコーポレーテッド|Phosphate binder that reduces the burden of tablets|

---

EP1698233A1|2005-03-01|2006-09-06|Bayer HealthCare AG|Reduction of digestibility of phosphorus in animal nutrition|

---

US20080058250A1|2005-08-17|2008-03-06|Allison Wren|Treatment of chronic renal failure and other conditions in domestic animals:compositions and methods|

---

US20110046059A1|2005-09-06|2011-02-24|Zelos Therapeutics, Inc.|Pharmaceutically acceptable formulations/compositions for peptidyl drugs|

---

WO2007130113A2|2005-09-06|2007-11-15|Zelos Therapeutics, Inc.|Parathyroid hormone analogues and methods of use|

---

US20070104799A1|2005-11-09|2007-05-10|Shire International Licensing B.V.|Treatment of chronic kidney diseasesubjects using lanthanum compounds|

---

US20070259052A1|2006-05-05|2007-11-08|Shire International Licensing B.V.|Assay for lanthanum hydroxycarbonate|

---

CA2690848A1|2007-06-07|2008-12-11|Jane E. Aubin|Estrogen receptor-related receptor gammain bone and cartilage formation and methods and compositions relating to same|

---

GB0806801D0|2008-04-15|2008-05-14|Immunodiagnostic Systems Ltd|Substrate|

---

MX350075B|2010-05-12|2017-08-25|Spectrum Pharmaceuticals Inc|Lanthanum carbonate hydroxide, lanthanum oxycarbonate and methods of their manufacture and use.|

---

WO2011156583A1|2010-06-10|2011-12-15|Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University|Isotopic biomarkers for rapid assessment of bone mineral balance in biomedical applications|

---

JP5876476B2|2010-06-11|2016-03-02|モリーコープ ミネラルズ エルエルシーＭｏｌｙｃｏｒｐ Ｍｉｎｅｒａｌｓ Ｌｌｃ|Improvement of bioactive compounds from wastewater|

---

WO2015038582A2|2013-09-11|2015-03-19|New York University|Methods and compositions for treating bone diseases|

---

AU2015226889B2|2014-03-07|2019-09-19|Secure Natural Resources Llc|Ceriumoxide with exceptional arsenic removal properties|

---

EP2932974A1|2014-04-15|2015-10-21|Chemische Fabrik Budenheim KG|Composition for prophylaxis and treatment of bone disorders|

法律状态:
2011-07-22| UUP| Utility model expired|

优先权:

---

申请号 | 申请日 | 专利标题

---

GBGB0015745.3A|GB0015745D0|2000-06-27|2000-06-27|Treatment of bone diseases|

---